Forecasts of Consolidated Financial Results for FY2025
| Millions of yen |
FY2024 Actual |
FY2025 Forecast |
YOY Actual |
YOY % |
| Net Sales |
64,139 |
75,000 |
10,860 |
16.9 |
| Operating profit |
5,331 |
6,800 |
1,468 |
27.5 |
| Ordinary profit |
5,107 |
6,800 |
1,692 |
33.1 |
| Profit attributable to owners of parent |
5,101 |
5,200 |
98 |
1.9 |
In the pharmaceutical business, which is the core business of the Group, despite the impact of annual NHI drug price revisions, we expect the increase in the lowest drug prices for essential drugs in the interim price revision and growth in gynecological products to contribute to our business results. In addition, due to the consolidation of financial results from the acquisition of Ha Tay Pharmaceutical Joint Stock Company, a Vietnamese pharmaceutical company, we project consolidated net sales of 75,000 million yen (up 16.9%YoY). In terms of profits, operating profit is expected to increase 27.5% YoY to 6,800 million yen and ordinary profit is expected to increase 33.1% YoY to 6,800 million yen, reflecting the increase in net sales. Projected profit attributable to owners of parent is 5,200 million yen (up 1.9% YoY).
Under the Medium-Term Management Plan that took effect beginning in FY2021, the Company is targeting Groupwide net sale of 70 billion yen, operating profit of 8%, and ROE of 8% in FY2025, as it aims to be a total healthcare company based on specialty pharma. The Company has maintained solid financial results thanks to the efforts of each Group company. In the next fiscal year, which is the final year of the current Medium-Term Management Plan, it will carry out Groupwide initiatives toward realization of these goals through further steady execution of growth strategies. In addition, we will further accelerate the expansion of our overseas business by making Ha Tay Pharmaceutical Joint Stock Company, a Vietnamese pharmaceutical company that is an equity-method affiliate, a consolidated subsidiary.